CV Sciences operates two distinct divisions: pharmaceuticals and consumer products. These divisions are supported by our medical and scientific advisory board, and state-of-the art production facilities.

Press Releases

CV Sciences, Inc. to Present at the Biotech Showcase™ 2018

LAS VEGAS, NV, January 3, 2018– CV Sciences, Inc., (OTCQB:CVSI) (the “Company,” “CV Sciences,” “our” or “we”), preeminent supplier and manufacturer of hemp-derived phytocannabinoids, including CBD oil and developer of specialty pharmaceutical therapeutics, announced today that it will be presenting at the Biotech Showcase™ 2018. The conference will be held January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco, California. Joseph Dowling, Chief Financial Officer of CV Sciences, Inc., will deliver the Company’s presentation and conduct meetings with investors.

Mr. Dowling’s presentation will highlight CV Sciences’ line of CBD consumer products as well as discuss its lead drug candidate, CVSI-007, which utilizes synthetically-formulated CBD for use in the treatment of smokeless tobacco addiction. Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences.

About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from or by visiting

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. 

Robert Haag
Managing Director
IRTH Communications
866-976- 4784

Leave a Reply

Your email address will not be published. Required fields are marked *

CV Sciences does not recruit through Facebook or any other social media sites. When applying for a job, please ensure you communicate with our HR Department: